

4 March 2025

Unveiling Vitasora: Managing Director, Marjan Mikel, to present on U.S. Growth plans, Major Deals & the Future of Connected Care

Respiri Limited (ASX:RSH; OTCQB:RSHUF) ("Respiri" or the "Company"), a Connected Care Management Company providing remote patient monitoring services on behalf of healthcare providers and organisations to patients in the USA, is pleased to invite shareholders and investors to a webinar on Monday 17 March 2025 at 11:00am AEDT;

Details of the webinar are as follow

Event: Respiri Market Update

Date/time: Monday 17 March 2025 at 11:00am AEDT

To register to attend the webinar, please follow the below link:

https://us06web.zoom.us/webinar/register/WN_oYucGOIIRI2id4dHJod9rQ

Investors are invited to submit questions via the Q&A function within the webinar, or prior to the webinar by sending them to justin@jmcorg.com.au.

-ENDS-

For further information, investors and media please contact:

Mr Marjan Mikel
CEO & Managing Director
Respiri Limited
P: +61 408 462 873
E: marjan@respiri.co

Mr Nicholas Smedley
Executive Chairman
Respiri Limited
P: +61 447 074 160
E: nicholas@respiri.co

This ASX announcement has been authorised for release by the Board of Directors of Respiri Limited.

About Respiri Limited – A Revolutionary Remote Healthcare Solutions Provider

Respiri Limited (ASX:RSH, OTCQB:RSHUF) is leading the charge in transforming healthcare delivery in the US. As an innovator in medical devices and MedTech, we combine state-of-the-art technologies with unparalleled clinical expertise. Partnering with healthcare providers and organisations we empower our clients to extend exceptional care into the community, making a real difference to patients' lives.

We are revolutionising healthcare one patient at a time with our disruptive business model, which provides personalised and responsive care. Our cutting-edge R&D sets us apart, offering comprehensive Care Management programs for all major chronic conditions, including our exclusive remote wheeze detection for respiratory disorders.

Through strategic partnerships, we seamlessly integrate our advanced solutions into existing systems and workflows, boosting efficiency and significantly reducing overall healthcare costs. Our data-driven programs and superior clinical expertise position us at the forefront of chronic disease management, ensuring patients' healthcare needs are met consistently and effectively across the continuum of care.

Learn more at www.respiri.co/au

About the wheezo® Medical Device

wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Respiri, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respiri™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians. For details on our US offering, visit <https://respiri.co/us> or for [wheezo®](#)

Respiri Limited is headquartered in Melbourne with offices in New York City and Miami.
wheezo® is a registered trademark of Respiri Limited